Approval · Notice of Compliance 25308 · 2021
LOVASTATIN: Notice of Compliance 25308
Issued February 26, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25308
- Date
- February 26, 2021
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in product ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVASTATIN | 02220172 | Marketed |
| LOVASTATIN | 02220180 | Marketed |
Medicinal ingredients
- LOVASTATIN 20 MG per TAB
- LOVASTATIN 40 MG per TAB